Leidos Holdings (LDOS) shares dropped 1.3% in pre-open trading today after BofA Securities downgraded the defense and information-technology contractor from Buy to Neutral on June 16, and reduced its price target to $125 from $200.
BofA flagged growing pressure within Leidos healthcare portfolio as the primary rationale for the change in stance, while still acknowledging that the companys defense business retains alignment with Department of Defense priorities. The call adds to a sequence of negative analyst moves that have lately influenced investor sentiment.
Earlier, Jefferies moved LDOS from Buy to Hold and trimmed its price target to $140 from $185, citing concerns that Leidos may find it difficult to maintain profit margins amid persistent uncertainty over U.S. defense spending. That downgrade, together with BofAs action, has intensified scrutiny of the companys near-term operating outlook.
Investor worries have been compounded by developments on the healthcare-contract front. Reports that the Defense Health Agency intends to transition away from Leidos as the lead systems integrator for its electronic health record system - a role Leidos has held since 2015 - have added negative sentiment around the companys healthcare segment.
The wider market provided little respite. The S&P 500 traded down about 0.6% and the Nasdaq fell roughly 1.2%, driven by a pronounced pullback in technology names and a rotation toward more economically sensitive sectors. The Dow Jones Industrial Average, by contrast, was up about 0.6%, illustrating a mixed session that offered no meaningful tailwind for a stock already trading close to its 52-week low of $113.28.
Taken together, the fresh BofA downgrade, the lingering impact of the Jefferies rating cut, concerns over the Defense Health Agency contract, and a risk-off tone in areas adjacent to technology have kept LDOS under pressure in pre-market trading. Over the past six months the shares have lost roughly one-third of their value, and with two major Wall Street firms recently reducing their ratings, near-term sentiment remains cautious.
Market context and investor outlook
Analysts point to the healthcare business as the central area of concern driving the latest reassessments of Leidos. While the defense segment continues to be recognized for its strategic fit with DoD priorities, the combined headwinds from contract transitions and margin uncertainty in a shifting defense spending environment are weighing on valuation expectations.
With the stock hovering near its annual low and key analysts trimming ratings and targets, investors appear to be adopting a conservative stance pending clearer signals on contract continuity, margin stability, and the broader markets appetite for tech-related names.
Summary
Leidos pre-market decline follows a substantive downgrade and price-target cut from BofA, adding to prior analyst downgrades and contract-related concerns in the healthcare segment. Mixed market performance and a pullback in tech have provided little offset, leaving the stock trading near its 52-week low.